Avendus advises Nichepharm Lifesciences and the Sobti Family, on its complete acquisition of 24% shares from Swedish-based Recipharm AB

This strategic maneuver marks a pivotal moment in Nichepharm’s trajectory. We remain committed to delivering cutting-edge pharmaceutical solutions, while upholding stringent standards of quality to ensure ongoing customer satisfaction. We are now poised to accelerate the company’s development initiatives, broaden its product portfolio, and explore new opportunities in global markets.

This strategic maneuver marks a pivotal moment in Nichepharm’s trajectory. We remain committed to delivering cutting-edge pharmaceutical solutions, while upholding stringent standards of quality to ensure ongoing customer satisfaction. We are now poised to accelerate the company’s development initiatives, broaden its product portfolio, and explore new opportunities in global markets.

Avendus is pleased that Sobti family has achieved a timely resolution of the shareholding structure of Nichepharm, which will allow them greater flexibility in accelerating the Company’s growth. We remain excited about its future prospects, given a large global market opportunity. We wish the family success in their continued quest to create sustainable value for all their stakeholders.

Avendus Wealth has had the privilege of partnering with the Sobti family over the past decade, supporting their wealth management needs. It has been a pleasure to guide them in securing the necessary funds to acquire the stake from their JV partner. We wish Nichepharm continued success as it embarks on the next phase of growth.